Transforming a new dimension in transcription-factor biology into next generation therapies
COR-H800 | Huntington’s Disease
-
Targeting the transcriptional drivers of neurodegeneration
COR-H800 blocks the HOX family of transcription factors that dominate pathological neuronal networks across all stages of Huntington’s disease. Separate from therapies targeting mutant huntingtin or somatic expansion, COR-H800 aims to reverse the downstream, potentially persistent gene dysregulation responsible for neuronal dysfunction and degeneration.
COR-S100 | Obesity & Type 2 Diabetes
-
Reprogramming metabolic dysfunction at its regulatory source
COR-S100 targets a master regulator linking fat accumulation,insulin resistance, and inflammation. Unlike therapies focused primarily on appetite, weight loss, or glucose control, COR-S100 aims to reverse the underlying pathological gene programs across metabolic tissues, addressing multiple drivers of cardiometabolic disease through a single target.